Table 2.

Overview of toxicity associated with regional hyperthermia therapy

Study	General	Fatigue	Myalgia	Anxiety	Genitourinary	Urethral pain	Cystitis	Dysuria	Hematuria	Bladder spasm	Weak urinary stream	Vaginitis	Frequency	Contracted bladder	Incontinence
Geijsen et al										10 (7%)
Hisazumi et al
Inman et al		2 (13%)	1 (7%)	1 (7%)		6 (40%)	4 (27%)		3 (20%)	2 (13%)	1 (7%)	1 (7%)
Masunaga et al
Nishimura et al *														1 (3%)
Noguchi et al													24 (69%)
Ohguri et al							3 (100%)
Petrovich et al *
Rietbroek et al
Sapozink et al		11 (26%)		6 (14%)						11 (26%)
Uchibayashi et al
Ueda et al								3 (27%)
van der Zee et al *
Wittlinger et al.														7 (16%)	1 (2%)

	Dermatologic	Burns/blister	Induration/ swelling	Pruitis	Rash	Bruising	Flushing	Fat necrosis	Neurologic	Dizziness	Confusion	Extrapyramidal sympoms	Infectious	Urinary tract infection
Geijsen et al
Hisazumi et al		21/39 (54%)	10/39 (26%)
Inman et al			4 (27%)	3 (20%)	2 (13%)	1 (7%)	1 (7%)			2 (13%)	1 (7%)	1 (7%)		2 (13%)
Masunaga et al
Nishimura et al *				3 (10%)				2 (6%)
Noguchi et al
Ohguri et al
Petrovich et al *		4 (8%)
Rietbroek et al		2 (14%)						5 (36%)
Sapozink et al				2 (5%)
Uchibayashi et al		15 (33%)	9 (20%)
Ueda et al
van der Zee et al *		5 (3%)	20 (11%)
Wittlinger et al.

	Cardiovascular	Hypertension	Gastrointestinal	Nausea or vomiting	Anorexia	Constipation	Ileus	Diarrhea	Abdominal pain	Procedure related	Positional discomfort	Heat intolerance/pain with applicator
Geijsen et al											22 (16%)	29 (20%)
Hisazumi et al
Inman et al		3 (20%)		2 (13%)		1 (7%)			5 (33%)			1 (7%)
Masunaga et al		0 (0%)						1 (4%)				12 (43%)
Nishimura et al *												18 (55%)
Noguchi et al				17 (49%)				4 (11%)
Ohguri et al								1 (33%)
Petrovich et al *		4 (8%)										25 (47%)
Rietbroek et al												31% of treat-ments
Sapozink et al				8 (19%)	11 (24%)							32 (74%)
Uchibayashi et al
Ueda et al
van der Zee et al *
Wittlinger et al.							1 (2%)	1 (2%)